Vector Labs Ab01053-7.1 Anti-TL1A [TAN2-2], Rat IgG2a, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: TAN2-2
Synonyms: Tnfsf15; bM20K13.3 (tumor necrosis factor (ligand) superfamily, member 15); MGC129934; MGC129935; TL1; TNF ligand-related molecule 1; TNF superfamily ligand TL1A; tumor necrosis factor (ligand) superfamily member 15; tumor necrosis factor (ligand) superfamily, member 15; tumor necrosis factor ligand 1B; Tumor necrosis factor ligand superfamily member 15; Vascular endothelial cell growth inhibitor; vascular endothelial growth inhibitor; vascular endothelial growth inhibitor-192A; VEGI; VEGI192A
Amount: 200 μg
Application Codes Clone: FC; IF; blocking; therapeutic
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG2a
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody is specific for TL1A, a member of the TNF ligand family. TL1A is expressed by endothelial cells, tissue macrophages, monocyte-derived dendritic cells, plasma cells and lamina propria-derived lymphocytes. Among peripheral blood cells, TL1A has been shown to be expressed predominantly by CD4+CCR9+ lymphocytes. Its expression has been shown to be induced by TNF alpha, IL-1 alpha and IFN gamma.
Application Notes: This antibody has been used in FACS analyses to reveal the role of TL1A in humoral immune responses and its mechanism of action in the development of collagen-induced arthritis (Wang et al, 2013), and in immunofluorescence confocal microscopy to demonstrate how chronic DR3 signaling could promote pathogenesis in inflammatory bowel disease (Taraban et al, 2011). The therapeutic potential of this antagonistic anti-TL1A antibody in countering the DR3–TL1A pathway in the inflammatory joint disease has been confirmed in both of the murine adjuvant-induced arthritis (AIA) and collagen-induced arthritis (CIA) models (Bull et al, 2008). In addition, this antibody has been demonstrated to prevent chronic colitis and attenuate established colitis by down-regulation of both T-helper 1 and T-helper 17 activation (Takedatsu et al, 2008).

Product Class:	Purified
Clone ID:	TAN2-2
Synonyms:	Tnfsf15; bM20K13.3 (tumor necrosis factor (ligand) superfamily, member 15); MGC129934; MGC129935; TL1; TNF ligand-related molecule 1; TNF superfamily ligand TL1A; tumor necrosis factor (ligand) superfamily member 15; tumor necrosis factor (ligand) superfamily, member 15; tumor necrosis factor ligand 1B; Tumor necrosis factor ligand superfamily member 15; Vascular endothelial cell growth inhibitor; vascular endothelial growth inhibitor; vascular endothelial growth inhibitor-192A; VEGI; VEGI192A
Amount:	200 μg
Application Codes Clone:	FC; IF; blocking; therapeutic
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG2a
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody is specific for TL1A, a member of the TNF ligand family. TL1A is expressed by endothelial cells, tissue macrophages, monocyte-derived dendritic cells, plasma cells and lamina propria-derived lymphocytes. Among peripheral blood cells, TL1A has been shown to be expressed predominantly by CD4+CCR9+ lymphocytes. Its expression has been shown to be induced by TNF alpha, IL-1 alpha and IFN gamma.
Application Notes:	This antibody has been used in FACS analyses to reveal the role of TL1A in humoral immune responses and its mechanism of action in the development of collagen-induced arthritis (Wang et al, 2013), and in immunofluorescence confocal microscopy to demonstrate how chronic DR3 signaling could promote pathogenesis in inflammatory bowel disease (Taraban et al, 2011). The therapeutic potential of this antagonistic anti-TL1A antibody in countering the DR3–TL1A pathway in the inflammatory joint disease has been confirmed in both of the murine adjuvant-induced arthritis (AIA) and collagen-induced arthritis (CIA) models (Bull et al, 2008). In addition, this antibody has been demonstrated to prevent chronic colitis and attenuate established colitis by down-regulation of both T-helper 1 and T-helper 17 activation (Takedatsu et al, 2008).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews